Equities research analysts expect Eagle Pharmaceuticals (NASDAQ:EGRX) to post earnings per share of $0.84 for the current quarter, according to Zacks. Two analysts have issued estimates for Eagle Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $1.11 and the lowest estimate coming in at $0.57. Eagle Pharmaceuticals posted earnings of $1.42 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 40.8%. The firm is expected to issue its next quarterly earnings results on Monday, May 14th.
According to Zacks, analysts expect that Eagle Pharmaceuticals will report full year earnings of $3.87 per share for the current year, with EPS estimates ranging from $3.68 to $4.06. For the next year, analysts expect that the business will post earnings of $4.25 per share, with EPS estimates ranging from $3.96 to $4.53. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Monday, February 26th. The specialty pharmaceutical company reported $0.84 EPS for the quarter, missing the consensus estimate of $1.00 by ($0.16). The company had revenue of $46.80 million for the quarter, compared to analyst estimates of $53.65 million. Eagle Pharmaceuticals had a return on equity of 34.16% and a net margin of 21.94%. The firm’s revenue was down 42.3% on a year-over-year basis. During the same period last year, the business earned $3.52 earnings per share.
Eagle Pharmaceuticals stock traded up $0.41 during midday trading on Thursday, hitting $53.97. 69,184 shares of the company were exchanged, compared to its average volume of 239,605. The firm has a market cap of $778.92, a price-to-earnings ratio of 15.98 and a beta of 1.38. Eagle Pharmaceuticals has a fifty-two week low of $45.05 and a fifty-two week high of $97.15. The company has a quick ratio of 3.88, a current ratio of 3.99 and a debt-to-equity ratio of 0.24.
In other Eagle Pharmaceuticals news, Director Sander A. Flaum sold 2,340 shares of the stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total transaction of $126,219.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 19.50% of the company’s stock.
A number of hedge funds have recently modified their holdings of EGRX. Municipal Employees Retirement System of Michigan boosted its position in Eagle Pharmaceuticals by 68.1% during the third quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock worth $191,000 after purchasing an additional 1,300 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Eagle Pharmaceuticals by 6.8% in the third quarter. Rhumbline Advisers now owns 17,076 shares of the specialty pharmaceutical company’s stock valued at $1,018,000 after acquiring an additional 1,080 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Eagle Pharmaceuticals by 15.2% in the third quarter. Bank of New York Mellon Corp now owns 134,277 shares of the specialty pharmaceutical company’s stock valued at $8,008,000 after acquiring an additional 17,767 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Eagle Pharmaceuticals by 60.8% in the third quarter. SG Americas Securities LLC now owns 4,511 shares of the specialty pharmaceutical company’s stock valued at $269,000 after acquiring an additional 1,706 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Eagle Pharmaceuticals by 4.2% in the third quarter. Ameriprise Financial Inc. now owns 138,619 shares of the specialty pharmaceutical company’s stock valued at $8,267,000 after acquiring an additional 5,548 shares in the last quarter.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.